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Abstract Prevalence of hypogonadism in men with cancer
has been reported between 40% and 90%,which is significantly
higher than in the general population. Hypogonadism is
likely to affect the quality of life in these patients by contributing
to non-specific symptoms, including decreased energy, anorex-
ia, sarcopenia, weight loss, depression, insomnia, fatigue, weak-
ness, and sexual dysfunction. Pathogenesis of hypogonadism in
cancer patients is thought to be multi-factorial. Inflammation
may play an important role, but leptin, opioids, ghrelin, and
high-dose chemotherapy through different mechanisms have all
been implicated as the cause. Hypogonadism is also associated
with poor survival in cancer patients. Data looking into the
treatment of hypogonadalmale cancer patients with testosterone
are limited. However, improvements in body weight, muscle
strength, lean bodymass, and quality of life have been shown in
hypogonadal men with other chronic diseases on testosterone
replacement therapy. Prospective and interventional trials are
needed to test the efficacy and safety of testosterone treatment
in improving quality of life of these patients.
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1 Introduction
Approximately 800,000 men are diagnosed with cancer
each year in the USA [1], and cancer treatments account
for more than $41 billion in spending each year [2]. Cancer
patients suffer from significant morbidity caused by the
primary disease directly or by the administration of chemo-
therapy or radiotherapy. They often present with non-
specific symptoms, including decreased energy, anorexia,
sarcopenia, weight loss, depression, insomnia, fatigue,
weakness, and sexual dysfunction. Some of these symp-
toms are known to be associated with hypogonadism in
patients with advanced cancer [3] and have a profound
impact in these individuals’ survival, quality of life, and
return to productivity. Here, we review the evidence of
the potential contribution of hypogonadism to symptom
burden in male patients with cancer, its pathophysiolo-
gy, and the potential therapeutic role of testosterone
replacement in this setting.
2 Prevalence of hypogonadism in non-cancer and cancer
patients
The prevalence of hypogonadism in non-cancer patients
increases with age. For example, in the Baltimore Longitudi-
nal Study of Aging, the incidence of hypogonadism was
approximately 20% in men over 60, 30% in men over 70,
and 50% in men over 80 years of age using total testosterone
levels <325 ng/dl as a criterion [4]. In the Massachusetts Male
Aging Study, a population-based cohort of men between ages
40 and 69 years, the estimated crude prevalence of androgen
deficiency at baseline and follow-up were 6% and 12%,
respectively [5]. In the Hypogonadism in Male (HIM) study
which included 2,162 men older than 45 years of age in the
primary care setting, the crude prevalence of hypogonadism
(defined as total testosterone <300 ng/dl) was 39% [6].
Prevalence of hypogonadism in cancer patients ranges
from 40% to 90% [7, 8]. In an early study, total testosterone
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levels in patients with pancreatic adenocarcinoma were sim-
ilar to the levels in control subjects [9]. Another study that
evaluated gonadal hormonal function of 44 adult males with
disseminated cancer found a prevalence of hypogonadism of
43% and 66% on the basis of total testosterone and free
testosterone, respectively. However, this study included pri-
marily malnourished cancer patients, in which 82% of
patients were less than 90% of ideal body weight [10]. Sex
hormone binding globulin (SHBG) levels are increased in
cancer patients, so measuring free and bioavailable testoster-
one is a more reliable and accurate way of determining
the gonadal status of male patients than total testoste-
rone level. Strasser et al. [3] reported a prevalence of
hypogonadism of 64% in advanced incurable cancer
patients based on free testosterone levels <35 ng/ml.
Our group published data showing that cancer patients
had mean total testosterone levels similar to the levels
in an age-matched non- cancer control group but signifi-
cantly lower levels of free and bioavailable testosterone
[7]. Recently, Fleishman et al. reported the prevalence
of hypogonadism in cancer patients based on total testos-
terone (TT, <300 ng/dl), free testosterone (FT, <52 pg/dl), and
bioavailable testosterone (BT, <95 ng/dl) to be 48%, 78%, and
66%, respectively [11].
Prevalence of hypogonadism is even higher in cancer
patients with a history of cachexia (described as weight loss
over the previous 6–12 months greater than 5%). In a Dutch
study, male cancer patients who had lost less than 10% of
their body weight had higher serum testosterone levels than
those with weight loss greater than 10% [12]. Our group
recently reported a strong association between BT and
SHBG and appetite levels [7]. Post-hoc analyses showed a
higher prevalence of hypogonadism defined as a BT<70 ng/
ml in cachectic subjects when compared to non-cachectic
subjects in this cohort.
3 Pathogenesis of hypogonadism in cancer
Although the exact mechanism of hypogonadism in cancer
patients is not entirely known, it is thought to be multi-
factorial. Patients with cancer may have a component of both
types of hypogonadism: primary (testicular, hypergonadotro-
phic, or with elevated luteinizing hormone—LH—and follic-
ular stimulating hormone—FSH) and secondary (central,
hypogonadotrophic, or with low or inappropriately normal
FSH and LH). Factors associated with primary hypogonadism
in this patient population include inflammatory cytokines and
chemotherapeutic agents. On the other hand, factors respon-
sible for the secondary/central hypogonadism include opioids,
glucocorticosteroids, low leptin levels, and/or high concentra-
tions of ghrelin (Fig. 1).
3.1 Inflammation
Inflammation is thought to play an important role in the
pathogenesis of hypogonadism in cancer patients. Can-
cer like other chronic diseases is a pro-inflammatory
state with elevated levels of inflammatory cytokines
[13, 14]. It has been postulated that cytokines may have
a direct effect on the hypothalamic–pituitary–gonadal
axis. This was supported by a study of 15 healthy male
subjects who were injected with subcutaneous recombi-
nant IL-6. Results showed that testosterone levels were
suppressed acutely in these healthy individuals after
IL-6 administration without apparent changes in gona-
dotrophin levels [15]. Also, animal data have suggested
that inflammatory cytokines may have an inhibitory
effect on Leydig cell steroidogenesis, thereby affecting
the hypothalamic–pituitary–gonadal axis at the level of
testes [16–18]. The mechanism by which IL-6 inhibits
the Leydig cell steroidogenesis is unclear, but it has
been postulated that it may negatively affect the activity
of 3β-hydroxysteroid dehydrogenase, one of the key
enzymes for testosterone synthesis [17].
On the other hand, Malkin et al. showed that 1 month
of testosterone replacement given to 27 male patients
with hypogonadism resulted in a statistically significant
reduction in inflammatory cytokines, including tumor
necrosis factor-alpha (TNF-α) and interleukin (IL)-1β
[19], and Kalinchenko et al. showed that testosterone
replacement decreased C-reactive protein (CRP), IL-1β,
and TNF-α in hypogonadal men with the metabolic
syndrome [20]. Similar immunosuppressive and anti-
inflammatory actions of androgens were seen in study
of patients with rheumatoid arthritis who were treated
with oral testosterone [21]. In light of these studies,
inflammation is likely to play a very important role in
the pathogenesis of hypogonadism in cancer patients,
and low testosterone can, in turn, exacerbate or maintain
the pro-inflammatory state forming a vicious circle.
3.2 Leptin
Leptin is a hormone secreted by adipocytes in propor-
tion to fat mass, and it is responsible for regulating
energy homeostasis (food intake and energy expendi-
ture) at the level of the hypothalamus. Also, it is re-
quired for normal LH and FSH secretion centrally and
production of testosterone in the gonads, providing the
link between nutrition and reproduction. It has been
proposed that low leptin levels (as seen in starvation
or in the setting of cachexia) function as a nutrient
sensor and provide a peripheral signal to the brain that
the environment may not be favorable for reproduction
due to unavailability of food, leading to a decrease in
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sex hormones. Both animal and human models have
shown that restoring normal levels of leptin results in
normalization of the hypothalamic–pituitary–gonadal
axis and reversal of infertility and delayed puberty
[22, 23], providing further support to this hypothesis.
Leptin replacement also has resulted in normalization of
starvation-induced fall in reproductive hormones in male
subjects [24]. As leptin is secreted by adipocytes, fat
atrophy can potentially cause hypogonadism by decreas-
ing leptin levels [25]. This could potentially explain the
higher prevalence of hypogonadism in cancer cachexia
subjects as they suffer from significant fat mass loss
and have been shown to have lower leptin levels than
subjects with cancer but without cachexia [26].
3.3 Ghrelin
Ghrelin is a 28-amino acid peptide which is primarily
involved in the control of food intake and growth hor-
mone secretion. Its levels increase in anticipation of a
meal and with weight loss correlating inversely with
leptin levels. Based on this, it also has been proposed
as a nutrient signal that links reproduction and nutrition.
Animal data show that systemic or intracerebral adminis-
tration of ghrelin causes significant inhibitory responses
in the secretion of LH and to a lesser extent FSH
[27–29]. In a male rat model, chronic ghrelin adminis-
tration resulted in a significant drop in serum LH and
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male subjects, ghrelin administration was associated with
significantly lower mean plasma levels of both LH and
testosterone than placebo [31]. Similar effects of ghrelin
on LH were published by Lanfranco et al. [32]. We
published that cancer patients had significantly higher
active ghrelin levels than healthy controls, and the ghre-
lin levels correlated inversely with free and bioavailable
testosterone [7]. All of these studies suggest that higher
levels of ghrelin through its inhibitory effects on LH can
contribute to hypogonadism in the setting of negative
energy balance as seen in patients with advanced cancer.
3.4 Opioids
Use of opioids in cancer patients is very common as these
patients suffer from significant pain from their primary
disease. It has been shown that opioids have the potential
of causing secondary hypogonadism in non-cancer patients
with pain [33–35]. The exact mechanism by which opioids
cause hypogonadism is not entirely known; however, a few
theories have been suggested. Opioids cause the disruption
of the normal pulsatility of gonadotrophin releasing hor-
mone (GnRH) secretion through δ-receptors present on
GnRH neurons [36]. They are also occasionally reported
to increase prolactin levels, thereby reducing testosterone
secretion [37]. Moreover, testosterone concentrations drop
more than 50% within a few hours of taking an opioid,
usually returning to baseline within 24–72 h after withdrawal
[38]. In a small observational study of 54 men taking oral
opioids includingmethadone for non-malignant pain, levels of
free and total testosterone were subnormal in 56% and 74% of
patients, respectively [39]. Similar results have been seen in
cancer patients. Fraser et al. reported a hypogonadism preva-
lence of 75% inmale cancer subjects receiving oral opioids for
chronic pain [40]. In another study, 18 out of 20 of male
cancer survivors who had received high-dose opioids orally
had lower total testosterone level compared to 8 out of 20
matched cancer survivors who did not receive opioids [8].
Taken together, the data strongly suggest that opioids play an
important role in the pathogenesis of hypogonadism in cancer
patients.
3.5 Chemotherapy
Alkylating and other chemotherapeutic agents at high doses
are known to cause hypogonadism in cancer patients. This is
believed to be related to the dose-dependent direct toxic
effect of these agents on the gonads especially on Leydig
cell function [41]. There have been multiple studies showing
elevated LH levels and low to normal testosterone levels in
cancer patients receiving chemotherapy, suggesting damage
of the hypothalamic–pituitary–gonadal axis at the testicular
level [42, 43]. Howell et al. [41] measured testosterone and
LH levels in 135 men treated for lymphomas. They found 44
men (31%) with significantly higher LH level compared to a
cohort of age-matched controls in the presence of a testoster-
one levels in the lower half of the normal range or frankly low.
However, it is important to note that non-standard, high
cumulative doses of chemotherapy are required to cause
significant and persistent impairment of Leydig cell func-
tion and subsequent hypogonadism in cancer patients.
4 Hypogonadism, symptom burden, and quality of life
in cancer patients
It has been suggested that androgen deficiency is an important
component of the Cancer Anorexia–Cachexia Syndrome
(CACS) [44]. Hypogonadism due to any cause significantly
affects quality of life in affected individuals and is associated
with symptoms such as decreased appetite, decreased energy
level and fatigue, insomnia, low libido, sexual dysfunction,
depressed mood, fatigue, sarcopenia, and weakness [45, 46].
Appetite and body weight are affected in cancer patients with
hypogonadism. In our previous work, we found a direct
correlation between appetite scores and free and bioavailable
testosterone in cancer patients [7]. Skipworth et al. showed
that hypogonadal cancer male patients experienced greater
percentage weight loss than eugonadal cancer patients
(16.7% vs. 11.3%) [47]. Chlebowski et al. reported a 66%
prevalence of hypogonadism in metastatic cancer patients,
where >80% of the patients were at <90% of ideal body
weight [10]. Todd and colleagues reported a negative cor-
relation of total testosterone with BMI and mid-arm cir-
cumference in men with advanced cancer [9].
Hypogonadism also affects the functional and emotional
well-being in cancer subjects. In a recently published study,
cancer survivors with hypogonadism had lower scores in
short-term health survey and functional assessment of chronic
illness—fatigue (FACIT-F) questionnaire suggesting poor
quality of life and increased fatigue in cancer patients [48].
Fleishman and colleagues [11] showed similar results in hypo-
gonadal cancer patients. They used Functional Assessment of
Cancer Therapy—Prostate (FACT-P) questionnaire to mea-
sure different aspects of quality of life and found that hypo-
gonadal cancer patients scored worse in the total as well as
physical and functional well-being component of the ques-
tionnaire when compared to eugonadal cancer subjects.
Strasser et al. showed that hypogonadal patients with cancer
(on the basis of low free testosterone) had higher scores in
anxiety and depression measured by Hospital Anxiety and
Depression Scale, lower functional and emotional well-being
measured by Functional Assessment of Cancer Therapy, and
higher fatigue measured by FACIT-F [3].
Sexual dysfunction is another problem that hypogonadal
cancer patients encounter. Most of the data on sexual
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dysfunction in cancer patients come from prostate cancer
studies [49, 50], which may not be a representative subgroup
to study given that part of the treatment of prostate cancer
includes induction of profound hypogonadism. Common fac-
tors that affect sexual function in cancer patients other than
hypogonadism include pelvic surgery, resulting in damage to
nerve/blood supply and radiation/chemotherapy-induced pe-
ripheral nerve damage. Greenfield and colleagues reported
greater degree of sexual dysfunction in cancer patients with
testosterone levels in lower quartiles compared to patients
with testosterone in high quartiles [48]. Similar results were
published by Fleishman et al. who reported lower scores in
FACT-P sexual function questionnaire in hypogonadal cancer
patients compared to eugonadal cancer patients [11].
Few other general symptoms have been linked to hypo-
gonadism. Del Fabbro et al. [51] recently showed that
hypogonadism in cancer patients is associated with insom-
nia. This was attributed to the disruption of normal circadian
rhythm and sleep. In the same study, the investigators also
found that lower testosterone levels were associated with
dyspnea. It was postulated that lower levels of testosterone
resulted in loss of lean body mass and wasting of respiratory
muscles, causing dyspnea.
5 Hypogonadism and cancer survival
To date, there has been only one study that looked into
survival of hypogonadal patients with cancer. The result of
this single center study showed that survival of male patients
with total testosterone levels <185 ng/dl was decreased
compared to patients with level of testosterone >185 ng/dl
(93 vs. 433 days) [51]. In another study, there was a trend
towards lower overall survival in patients with baseline low
testosterone who were receiving anti-androgen therapy for
prostate cancer [52]. Whether hypogonadism contributes to
a decrease in survival by a not well-characterized mecha-
nism or is simply a marker of severity of disease is not
known.
6 Treatment of hypogonadism in cancer patients
In non-cancer, hypogonadal men, testosterone replacement
has a positive effect on several parameters that are also
impaired in the setting of cancer, and treatment of hypogo-
nadism is clinically indicated in symptomatic men with low
testosterone [53]. Furthermore, testosterone administration
has been shown to increase lean body mass and bone mineral
density, to improve quality of life, and to decrease fatigue in
this setting [54, 55]. Sexual function and mood parameters
improve rapidly and are maintained throughout testosterone
treatment [56, 57]. Also, testosterone replacement reduces
cytokine levels in hypogonadal men [19, 20] and induces a
reduction in inflammatory markers and clinical remission in
other hypogonadal states such as arthritis [21].
Treatment of hypogonadism in HIV patients with wasting
has been beneficial. Previous studies have shown improve-
ment in body weight, muscle strength, lean body mass, and
improved quality of life in HIV patients on testosterone
replacement therapy [58–60]. Whether similar benefits will
apply to hypogonadal cancer patients is not known.
Chlebowski et al. showed decreased severity of weight loss
in cancer patients who were treated with nandrolone [10].
However, Loprinzi and colleagues did not show any benefit
of fluoxymesterone, an anabolic corticosteroid which was
found to be inferior to dexamethasone and megestrol with
respect to appetite enhancement [61]. Certainly, there is
paucity of data when it comes to interventional studies
looking at the safety and efficacy of testosterone in this
patient population, although several studies are ongoing
using testosterone or selective androgen receptor modu-
lators (SARMs) which would potentially present the
advantage of good oral bioavailability and decreased pros-
tatic and virilizing side effects. Recently, a phase II study
using the SARM ostarine was reported to cause a dose-
dependent increase in lean body mass and functional perfor-
mance [62].
7 Conclusion
The development of therapies for the prevention or
treatment of cancer-related symptoms is desperately
needed because they significantly reduce quality of life
in these patients. The prevalence of hypogonadism is
higher in cancer patients than in non-cancer patients. It
is associated with poor quality of life, and it likely
contributes to weight loss, sexual dysfunction, fatigue,
and weakness. Hypogonadism is also associated with
poor survival in cancer patients. Data regarding the
effectiveness and safety of testosterone treatment in this
population are scant, and more prospective trials are
needed to determine if testosterone replacement therapy
will improve muscle mass and strength, quality of life,
sexual function, and fatigue in this setting.
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